INDUSTRY

migraine and covid-19

Covid-19 & migraine and other headaches: Webinar by Vall d’Hebron

Watch the first webinar for patients on Covid-19 and its impact on migraine and other headaches streamed by Vall d’Hebron Hospital with the support of EMHA.

Learn about the impact of the virus on patients with migraine, the possible risks associated with the treatments and advice on reducing the negative  impact of the lock down during migraine and other headaches episodes.

European Migraine Day of Action with MEPS in the European Parliament

Each year, September 12th is the European Migraine Day of Action. Today, EMHA’s President and Executive Director have been invited by MEP Esteban Gonzalez Pons and MEP Dolors Montserrat to the European Parliament to discuss about how to better help the affected ones to give light to the disease and how to improve the life …

European Migraine Day of Action with MEPS in the European Parliament Read More »

New drugs, decades in the making, are providing relief for migraines.

Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she …

New drugs, decades in the making, are providing relief for migraines. Read More »

“Green light” to Lilly’s monoclonal antibody to migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes …

“Green light” to Lilly’s monoclonal antibody to migraine Read More »

Scroll to Top